You just read:

Final Patient Completes Prosonix' Phase 2 Clinical Study with PSX1002 in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

News provided by

Prosonix

16 Aug, 2013, 09:00 BST